SOAT1 and vitiligo: According to the guidelines, the first-line use of topical calcineurin inhibitors in pediatric vitiligo, like tacrolimus, has shown effectiveness for depigmentation on the head and neck with intermediate response on the trunk and extremities [10]. JAK/STAT inhibitors like ruxolitinib in patients 12 years and older have been FDA-approved since 2022 for vitiligo affecting less than 10% of the body surface area [10].